Clinical Trial Update: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

View source ↗

Summary

This clinical trial update announces ongoing recruitment for a study of trastuzumab deruxtecan in adults with HER2-positive advanced gastric cancer or gastroeso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | Status: RECRUITING